WOBURN, Mass. , Nov. 26, 2019 (GLOBE NEWSWIRE) — Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke , Executive Chairman and Director of Replimune , will present and